BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...in the first-line setting.At the 2018 meeting of the American Society of Clinical Oncology, AstraZeneca plc...
...in Phase I testing for COVID-19. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

...including the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc...
...politically aligned with Trump.  Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...as a new indication for these technologies.On Monday, Grail announced collaborations with Amgen Inc. (NASDAQ:AMGN), AstraZeneca plc...
BioCentury | Jan 15, 2021
Regulation

EMA provides update on data breach, highlighting data security risk for sector

...attempted cybertheft of American research on vaccine development. And in November reports surfaced of AstraZeneca plc...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc...
BioCentury | Jan 15, 2021
Politics, Policy & Law

Biden signals new path for Warp Speed, names Kessler to replace Slaoui

...with President Donald Trump. Unlike Slaoui, who focused his career on developing vaccines at GlaxoSmithKline plc...
...fellow in the Obama administration’s Office of Cabinet Affairs. Steve Usdin U.S. Food and Drug Administration (FDA) GlaxoSmithKline plc Johnson...
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...By BioCentury Staff After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals...
BioCentury | Jan 15, 2021
Product Development

Phase I/II antibody levels support single shot for J&J COVID-19 vaccine: Data Byte

...doses, of the viral vector vaccine from AstraZeneca plc...
BioCentury | Jan 15, 2021
Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

...data from the Phase III ADAPT-2 trial that a combination of Vivitrol naltrexone from Alkermes plc...
BioCentury | Jan 13, 2021
Politics, Policy & Law

Woodcock to serve as acting FDA commissioner, Sharfstein a contender for top FDA job

...including the decision to restrict the use of the diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc...
Items per page:
1 - 10 of 25929